OncoCyte Corp (OCX)
2.71
+0.04
(+1.50%)
USD |
NASDAQ |
Nov 22, 10:52
OncoCyte Gross Profit Margin (Quarterly): 43.48% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 43.48% |
| June 30, 2024 | 48.08% |
| March 31, 2024 | -55.68% |
| December 31, 2023 | -37.26% |
| September 30, 2023 | 57.81% |
| June 30, 2023 | 58.75% |
| March 31, 2023 | 3.37% |
| December 31, 2022 | -9.85% |
| September 30, 2022 | -401.5% |
| June 30, 2022 | 13.08% |
| Date | Value |
|---|---|
| March 31, 2022 | 65.00% |
| December 31, 2021 | -134.1% |
| September 30, 2021 | -88.01% |
| June 30, 2021 | -19.41% |
| March 31, 2021 | 7.03% |
| December 31, 2020 | -42.35% |
| September 30, 2020 | -8.29% |
| June 30, 2020 | -155.2% |
| March 31, 2020 | -981.2% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-981.2%
Minimum
Mar 2020
65.00%
Maximum
Mar 2022
-86.12%
Average
-9.85%
Median
Dec 2022
Gross Profit Margin (Quarterly) Benchmarks
| Fonar Corp | 40.24% |
| XWELL Inc | 24.38% |
| ProPhase Labs Inc | -5.24% |
| Applied DNA Sciences Inc | 30.75% |
| Veracyte Inc | 68.19% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -211.4% |
| Return on Assets | -57.93% |
| Return on Invested Capital | -211.4% |
| Profit Margin (Quarterly) | -11.73K% |
| Operating Margin (Quarterly) | -5.54K% |
| Return on Net Operating Assets | -68.41% |